An example of clinical trials involving combination biologics is the phase 2 evaluation of dazodalibep, a CD40L inhibitor, in combination with anti-TNF medications (etanercept or adalimumab) is underway in RA patients with inadequate response to anti-TNF treatment (NCT05306353). The gene discussed is TNF; the disease is rheumatoid arthritis.